Response to primary systemic treatment by tumor type and its effect on the extent of the subsequent breast surgery - single center experience
Association of Breast Surgery ePoster Library. Daskalova I. 05/15/17; 166197; P149
Ms. Iskra Daskalova
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction: Primary systemic treatment (PST) in selected breast cancer (BC) patients has become more common in the last decade. We evaluated the effect of PST on the extent of subsequent breast surgery.
Methods: Between September 2014 and November 2016 34 BC patients (stage II-III) underwent PST followed by surgery in our institution. One was treated with primary hormonal treatment (5 months), the other 33 received chemotherapy. Twenty four of the patients had luminal Her2 negative tumors, 3 were luminal Her2 positive (triple positive), 3 were non-luminal Her2 positive (Her2 type), and 4 were triple negative.
Results: Of 24 patients with luminal type, 4 had pCR (16,6%). None of the 3 triple positive patients had pCR or significant downsizing. One of the 3 patients with Her2 type had pCR (33%). None of 4 triple negative patients had pCR, however 3 (75%) had almost complete response, defined as at least 85% reduction of the primary tumor size. Out of 15 patients initially considered for mastectomy, 5 (33%) converted to lumpectomy after PST – 3 out of 10 luminal (30%), 1 Her2 type, and 1 triple negative. None of the 3 triple positive patients converted.
Conclusion: Our results support the use of PST in all tumor types BC, except triple positive. The likelihood of pCR or almost complete response was highest in Her2 type or triple negative. The effect of PST in luminal tumors was sufficient to convert 30% of them to less extensive breast surgery. No triple positive patients had a significant response.
Methods: Between September 2014 and November 2016 34 BC patients (stage II-III) underwent PST followed by surgery in our institution. One was treated with primary hormonal treatment (5 months), the other 33 received chemotherapy. Twenty four of the patients had luminal Her2 negative tumors, 3 were luminal Her2 positive (triple positive), 3 were non-luminal Her2 positive (Her2 type), and 4 were triple negative.
Results: Of 24 patients with luminal type, 4 had pCR (16,6%). None of the 3 triple positive patients had pCR or significant downsizing. One of the 3 patients with Her2 type had pCR (33%). None of 4 triple negative patients had pCR, however 3 (75%) had almost complete response, defined as at least 85% reduction of the primary tumor size. Out of 15 patients initially considered for mastectomy, 5 (33%) converted to lumpectomy after PST – 3 out of 10 luminal (30%), 1 Her2 type, and 1 triple negative. None of the 3 triple positive patients converted.
Conclusion: Our results support the use of PST in all tumor types BC, except triple positive. The likelihood of pCR or almost complete response was highest in Her2 type or triple negative. The effect of PST in luminal tumors was sufficient to convert 30% of them to less extensive breast surgery. No triple positive patients had a significant response.
Introduction: Primary systemic treatment (PST) in selected breast cancer (BC) patients has become more common in the last decade. We evaluated the effect of PST on the extent of subsequent breast surgery.
Methods: Between September 2014 and November 2016 34 BC patients (stage II-III) underwent PST followed by surgery in our institution. One was treated with primary hormonal treatment (5 months), the other 33 received chemotherapy. Twenty four of the patients had luminal Her2 negative tumors, 3 were luminal Her2 positive (triple positive), 3 were non-luminal Her2 positive (Her2 type), and 4 were triple negative.
Results: Of 24 patients with luminal type, 4 had pCR (16,6%). None of the 3 triple positive patients had pCR or significant downsizing. One of the 3 patients with Her2 type had pCR (33%). None of 4 triple negative patients had pCR, however 3 (75%) had almost complete response, defined as at least 85% reduction of the primary tumor size. Out of 15 patients initially considered for mastectomy, 5 (33%) converted to lumpectomy after PST – 3 out of 10 luminal (30%), 1 Her2 type, and 1 triple negative. None of the 3 triple positive patients converted.
Conclusion: Our results support the use of PST in all tumor types BC, except triple positive. The likelihood of pCR or almost complete response was highest in Her2 type or triple negative. The effect of PST in luminal tumors was sufficient to convert 30% of them to less extensive breast surgery. No triple positive patients had a significant response.
Methods: Between September 2014 and November 2016 34 BC patients (stage II-III) underwent PST followed by surgery in our institution. One was treated with primary hormonal treatment (5 months), the other 33 received chemotherapy. Twenty four of the patients had luminal Her2 negative tumors, 3 were luminal Her2 positive (triple positive), 3 were non-luminal Her2 positive (Her2 type), and 4 were triple negative.
Results: Of 24 patients with luminal type, 4 had pCR (16,6%). None of the 3 triple positive patients had pCR or significant downsizing. One of the 3 patients with Her2 type had pCR (33%). None of 4 triple negative patients had pCR, however 3 (75%) had almost complete response, defined as at least 85% reduction of the primary tumor size. Out of 15 patients initially considered for mastectomy, 5 (33%) converted to lumpectomy after PST – 3 out of 10 luminal (30%), 1 Her2 type, and 1 triple negative. None of the 3 triple positive patients converted.
Conclusion: Our results support the use of PST in all tumor types BC, except triple positive. The likelihood of pCR or almost complete response was highest in Her2 type or triple negative. The effect of PST in luminal tumors was sufficient to convert 30% of them to less extensive breast surgery. No triple positive patients had a significant response.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}